EMA Recommends Granting a Marketing Authorisation for Vimseltinib By Ogkologos - September 5, 2025 96 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of adults with symptomatic tenosynovial giant cell tumour Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Accordpharma Enzalutamide FDA Approves Durvalumab for Resectable Gastric or Gastro-Oesophageal Junction Adenocarcinoma Ahead of ESMO Immuno-Oncology Congress 2025: topics at a glance MOST POPULAR 关于肺癌生物标志物检测应当了解的信息：专家问答 April 13, 2023 Can’t Sleep? Tips for Coping with Insomnia August 4, 2021 Abiraterone Acetate Plus Prednisone and LHRH Analogue is Active and Safe... October 4, 2021 Por qué la Reunión Anual de la American Society of Clinical... June 1, 2021 Load more HOT NEWS Selpercatinib Shows Durable Efficacy in RET Fusion–positive NSCLC Skull Implant Delivers Drugs with Precision, Offering Hope for Parkinson’s, Cancer,... Adding Checkpoint Inhibition to Anti-HER2 Breast Cancer Therapy Brings no Benefit... FDA Approves Enfortumab Vedotin-ejfv with Pembrolizumab for Locally Advanced or Metastatic...
